Evidence map›Paper›PMID 35050719›Full record

ReviewFuture medicinal chemistry2022

Antibacterial pyrazoles: tackling resistant bacteria.

Mohammad A Alam

Abstract readReview
In one paragraph

Review in Future medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Synthesis of Pyrazole-Based Inhibitors of the Bacterial EnzymeInternational journal of molecular sciences · 2024
    Article
  15. Novel Isoxazole-Based Antifungal Drug Candidates.International journal of molecular sciences · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mohammad A AlamDepartment of Chemistry & Physics, College of Sciences & Mathematics, Arkansas State University, Jonesboro, AR 72401, USA.ORCID 0000-0003-0258-3732

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett, JERRY WARE · 2012 to 2026
$60.9M
NIGMS NIH HHS P20 GM103429
6 · The paper itself

Abstract

Bacterial resistance to antibiotics threatens our progress in healthcare, modern medicine, food production and ultimately life expectancy. Antibiotic resistance is a global concern, which spreads rapidly across borders and continents due to rapid travel of people, animals and goods. Derivatives of metabolically stable pyrazole nucleus are known for their wide range of pharmacological properties, including antibacterial activities. This review highlights recent reports of pyrazole derivatives targeting different bacterial strains focusing on the drug-resistant variants. Pyrazole derivatives target different metabolic pathways of both Gram-positive and Gram-negative bacteria.

Indexed as

Alkyl and Aryl TransferasesAnti-Bacterial AgentsCell WallDNA GyraseDrug Resistance, Multiple, BacterialGram-Negative BacteriaGram-Positive BacteriaPyrazolesTetrahydrofolate DehydrogenaseAlkyl and Aryl TransferasesAnti-Bacterial AgentsDNA GyrasePyrazolesTetrahydrofolate Dehydrogenaseundecaprenyl pyrophosphate synthetaseAcinetobacter baumanniiantibacterialantibioticsantimicrobialsbacterial resistancedrug-resistantESKAPE pathogensMRSApyrazole

Identifiers

PMID35050719
PMCPMC8890142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.